Overview

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-08

Target enrollment:

Participant gender:

Summary

To investigate the efficacy and safety of neoadjuvant treatment with Tislelizumab combined with chemotherapy for initially unresectable N2/III non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Drug Therapy
Platinum Compounds